Cytosponge awarded Best Medical Technology at Prix Galien Awards

Regarded as the industry’s equivalent of a Nobel Prize, Prix Galien is dedicated to honouring innovation in life sciences.

The Cytosponge was chosen against a strong list of industry leading innovation, recognising it as a game-changer for both patients and health systems.

Cyted has accelerated access to the Cytosponge test across the UK, with successful pilots ongoing for the detection and monitoring of Barrett’s oesophagus – a known precursor to oesophageal cancer – with expansion into primary care underway.

Now available in hospitals across England, the Cytosponge offers a way to triage and prioritise patients for endoscopy and tackle the NHS backlog.

With the Cytosponge, signs of cancer are picked up much earlier, improving survival rates in a cancer with typically poor outcomes. The Cytosponge is also supporting the NHS in its recovery by cutting patient wait times and pressure on endoscopy services.

Best Medical Technology was open to any instrument, apparatus, appliance, software or other article (whether used alone or in combination together with any accessories, including software used specifically for diagnostic and/or therapeutic purposes) that has had a significant, positive impact on improving patient lives.

Marcel Gehrung, CEO and Co-Founder at Cyted, comments: “This is a huge moment for Cyted and the Cytosponge. I am immensely proud that the Cytosponge has been awarded Best Medical Technology by Prix Galien.

“At Cyted, our ultimate objective is to make the Cytosponge a routine test for millions of patients at risk, both in the UK and beyond, preventing tens of thousands of deaths from advanced oesophageal cancer every year.”